Bill dismantles vaccine injury fund, opens manufacturers to unlimited lawsuits

What it does

This bill eliminates the liability shield that currently protects vaccine manufacturers and administrators from lawsuits over vaccine injuries. It allows people to sue manufacturers and administrators directly in state or federal court for damages from vaccine-related injuries or deaths, but requires them to choose: either pursue compensation through the existing federal Vaccine Injury Compensation Program (VICP) or file a civil lawsuit—not both. It also removes COVID-19 vaccines from a separate federal liability shield for emergency countermeasures.

Why we flagged it

The bill's core mechanism is the removal of statutory liability shields and the restoration of tort remedies against vaccine manufacturers. This is functionally a deregulation of vaccine liability—shifting risk from a no-fault federal program to the civil courts and manufacturers themselves.

• Section (b) excludes COVID-19 vaccines from the definition of 'covered countermeasure' under the Public Readiness and Emergency Preparedness (PREP) Act. This is substantively unrelated to the bill's core purpose (ending the VICP liability shield) and appears to target a specific vaccine class outside the main statutory scheme being amended.

What the text implies

• Dismantling the no-fault VICP system may shift burden of proof to injured persons, requiring them to prove negligence or defect in court—a much higher bar than the VICP's causation standard, potentially leaving many injured persons without remedy.
• Unlimited tort liability exposure may cause vaccine manufacturers to exit the market, consolidate, or raise prices sharply, reducing vaccine availability and affordability for low-income and uninsured populations.
• The bill creates a one-way election: once a person chooses the civil court route, they forfeit VICP compensation; conversely, VICP award bars civil suit. This may trap injured persons in an unfavorable choice if litigation costs exceed expected recovery.
• Removal of COVID-19 vaccines from PREP Act coverage may expose manufacturers to retroactive liability for vaccines already administered under emergency authorization, creating massive contingent liabilities and potential bankruptcy risk.
• State-level variation in tort law, damages caps, and statute of limitations will create a patchwork of vaccine liability regimes, potentially incentivizing forum shopping and destabilizing the national vaccine supply chain.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

While the bill restores tort remedies for vaccine-injured persons (a potential benefit), it dismantles the no-fault Vaccine Injury Compensation Program's protections—which historically provided faster, more certain compensation without proving negligence—and exposes manufacturers to unlimited liability, likely raising vaccine prices, reducing manufacturer participation, and potentially disrupting vaccine supply and development. The net effect on ordinary citizens is likely negative: fewer vaccin

Who stands to gain

• personal injury law firms (increased litigation volume)
• litigation finance companies (funding vaccine injury lawsuits)

Named in the bill

vaccine manufacturers, vaccine administrators, National Vaccine Injury Compensation Program (VICP), Public Health Service Act, PREP Act (Public Readiness and Emergency Preparedness Act), FDA (emergency use authorization), U.S. Court of Federal Claims, state and federal courts

Where it stands

1 cosponsor: 1 Republicans.

• Feb 11, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Feb 11, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.